Patents by Inventor Giovanni Marsicano

Giovanni Marsicano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
    Publication number: 20230226076
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Application
    Filed: September 15, 2022
    Publication date: July 20, 2023
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Mathilde METNA, Stéphanie MONLEZUN, Arnau BUSQUET-GARCIA, Daniela COTA, Giovanni MARSICANO, Jean-Michel REVEST, Monique VALLEE
  • 3?-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders
    Patent number: 11484537
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 1, 2022
    Assignees: AELIS FARMA, INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUX
    Inventors: Pier Vincenzo Piazza, Sandy Fabre, Mathilde Metna, Stéphanie Monlezun, Arnau Busquet-Garcia, Daniela Cota, Giovanni Marsicano, Jean-Michel Revest, Monique Vallée
  • ANTAGONISTS OF CB1 RECEPTOR
    Publication number: 20220153776
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Application
    Filed: October 7, 2021
    Publication date: May 19, 2022
    Inventors: Pier Vincenzo PIAZZA, Monique VALLEE, Giovanni MARSICANO, Francois-Xavier FELPIN, Luigi BELLOCCHIO, Daniela COTA, Jean-Michel REVEST, Sergio VITIELLO, Umberto SPAMPINATO, Rafael MALDONADO
  • 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
    Publication number: 20220017562
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Stéphanie MONLEZUN, Mathilde METNA, Monique VALLEE, Jean-Michel REVEST, Daniela COTA, Giovanni MARSICANO, Aline MARIGHETTO, Andrés OZAITA, Rafael MALDONADO
  • 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
    Publication number: 20210030768
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 4, 2021
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Mathilde METNA, Stephanie MONLEZUN, Arnau BUSQUET-GARCIA, Daniela COTA, Giovanni MARSICANO, Jean-Michel REVEST, Monique VALLEE
  • ANTAGONISTS OF CB1 RECEPTOR
    Publication number: 20190071465
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Application
    Filed: October 24, 2018
    Publication date: March 7, 2019
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUX
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
  • Antagonists of CB1 receptor
    Patent number: 10150793
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 11, 2018
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUX
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
  • Antagonists of CB1 receptor
    Patent number: 10040816
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 7, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Bordeaux
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
  • Antagonists of CB1 Receptor
    Publication number: 20160145294
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Application
    Filed: February 1, 2016
    Publication date: May 26, 2016
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
  • Antagonists of CB1 Receptor
    Publication number: 20140200200
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 17, 2014
    Applicants: UNIVERSITE DE BORDEAUX I, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIV DE BORDEAUX II VICTOR SEGALEN
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado